advent
clinic
use
polymeras
chain
reaction
pcr
technolog
revolution
diagnosi
viral
respiratori
infect
earli
studi
demonstr
much
greater
sensit
viral
cultur
clinic
action
time
result
pcr
therefor
essenti
replac
viral
cultur
acut
clinic
diagnosi
pcr
unclear
relationship
acut
convalesc
serolog
prior
diagnost
standard
clinic
use
except
retrospect
diagnosi
pcr
detect
presenc
viral
genom
materi
time
specimen
acquisit
usual
repres
acut
infect
although
prolong
shed
viral
genom
materi
acut
infect
occur
especi
immunocompromis
patient
multiplex
platform
perform
respiratori
viral
panel
rvp
becom
norm
mani
hospit
initi
drive
forc
multiplex
panel
season
influenza
outbreak
year
strain
influenza
circul
strain
resist
oseltamivir
strain
remain
sensit
time
differenti
influenza
b
strain
influenza
becam
critic
order
discontinu
dual
antivir
therapi
subsequ
year
pandem
strain
influenza
viru
ad
addit
target
multiplex
rvp
assay
complet
replac
respiratori
viral
cultur
rvp
includ
clinic
import
viral
assay
use
epidemiolog
purpos
respiratori
syncyti
viru
rsv
adenoviru
panel
becam
progress
extens
includ
addit
newli
discov
human
respiratori
viral
pathogen
coronavirus
respons
sever
acut
respiratori
syndrom
sar
human
metapneumoviru
hmpv
initi
perceiv
simpli
posit
altern
signific
pathogen
detect
frequent
associ
rhinoviru
respiratori
tract
diseas
led
routin
inclus
rvp
panel
increasingli
subspeci
virus
influenza
ad
made
dramat
clear
recent
epidem
enteroviru
ev
detect
human
rhinoviru
multiplex
assay
other
ev
speci
seem
distinct
trophism
c
mainli
caus
respiratori
tract
diseas
final
pcr
bacteri
speci
difficult
grow
mycoplasma
spp
chlamydophila
spp
differenti
respiratori
tract
infect
bordetella
pertussi
ad
conveni
increas
diagnost
yield
spectrum
caus
cover
multiplex
rvp
list
box
unfortun
current
multiplex
rvp
panel
provid
laboratori
diagnos
viral
respiratori
tract
diseas
clinic
treatment
option
disconnect
diagnosi
specif
treatment
rais
difficult
manag
issu
tendenc
ignor
result
posit
assay
rvp
panel
influenza
atyp
bacteri
pathogen
includ
clearli
action
cover
articl
issu
articl
evalu
manag
respiratori
virus
commonli
detect
multiplex
rvp
review
pcr
also
standard
diagnosi
mani
viral
infect
either
rare
eg
hantaviru
syndrom
middl
east
respiratori
syndrom
mer
rare
involv
lung
high
clinic
suspicion
infect
requir
order
pcr
assay
specif
discuss
articl
given
limit
repertoir
treatment
option
viral
respiratori
tract
infect
care
assess
clinic
signific
posit
pcr
viru
influenza
need
gener
indic
treatment
posit
rvp
influenza
presenc
high
risk
subsequ
develop
lower
respiratori
tract
lrt
infect
lrti
box
give
gener
approach
evalu
posit
rvp
one
major
question
whether
posit
rvp
repres
diseas
simpli
colon
prolong
shed
prior
unrel
infect
mani
viral
syndrom
may
minim
symptom
yet
lead
posit
screen
test
sever
virus
also
demonstr
prolong
shed
symptomat
ill
prolong
shed
particular
problem
immunocompromis
exact
popul
viral
pneumonia
like
requir
treatment
perspect
frequenc
colon
prolong
asymptomat
shed
gain
studi
healthi
patient
present
noninfecti
clinic
visit
colon
clearli
common
asymptomat
children
adult
extrarespiratori
tract
involv
odd
ratio
greater
influenza
rsv
hmpv
least
greater
adenoviru
bocaviru
coronavirus
ev
parainfluenza
rhinoviru
frequenc
posit
nasopharynx
np
pcr
test
actual
greater
asymptomat
control
case
pneumonia
contrast
detect
common
respiratori
viru
asymptomat
adult
adult
even
rhinoviru
highli
associ
pneumonia
odd
ratio
greater
common
viru
detect
asymptomat
adult
coronavirus
although
detect
still
associ
odd
ratio
pneumonia
greater
second
critic
issu
site
sampl
posit
sampl
lrt
carri
signific
posit
sampl
np
oropharynx
op
posit
viral
sampl
np
op
swab
eas
obtain
specimen
lower
respiratori
tract
sampl
obtain
greater
signific
posit
bronchoalveolar
lavag
sampl
much
like
indic
viral
pneumonia
np
op
swab
expector
sputum
endotrach
aspir
repres
viral
tracheobronch
intermedi
risk
viral
pneumonia
probabl
concern
aspect
site
sampl
find
patient
posit
lrti
occasion
neg
np
op
swab
may
result
poor
sampl
techniqu
np
op
swab
may
actual
repres
transit
upper
respiratori
tract
urt
lrt
diseas
major
concern
seen
patient
influenza
ainduc
acut
respiratori
distress
syndrom
ard
preliminari
data
suggest
high
qualiti
sputum
sampl
patient
radiograph
pneumonia
may
posit
often
np
op
swab
even
common
virus
influenza
obtain
lrt
sampl
patient
capinduc
respiratori
failur
prudent
even
np
op
swab
neg
influenza
risk
progress
viral
urt
infect
pneumonia
ard
gener
unclear
nonspecif
presenc
peripher
monocytosi
demonstr
associ
pneumonia
adenovir
infect
stem
cell
transplant
smoke
steroid
total
bodi
irradi
lymphopenia
associ
progress
lrti
investig
suggest
detect
multipl
respiratori
virus
portend
poor
prognosi
may
marker
occult
immuncompromis
tempor
pattern
symptom
assess
tempo
diseas
progress
also
key
understand
signific
posit
rvp
long
durat
interv
sinc
onset
urt
symptom
follow
new
chang
symptom
consist
lrt
system
infect
suggest
pulmonari
infiltr
patient
posit
np
op
swab
like
bacteri
superinfect
primari
viral
pneumonia
case
posit
np
op
rvp
like
repres
persist
shed
anteced
viral
uri
convers
neg
rvp
situat
may
result
seroconvers
lead
discord
result
serolog
rvp
seen
epidemiolog
studi
persist
worsen
uri
symptom
suggest
posit
np
op
rvp
may
caus
tracheobronch
pneumonia
far
import
factor
decis
treat
posit
rvp
immun
statu
patient
patient
viral
pneumonia
may
immunocompromis
dissemin
diseas
includ
viremia
much
like
sever
immunocompromis
type
immunocompromis
associ
progress
viral
pneumonia
poorli
studi
probabl
greatest
risk
recent
human
stem
cell
bone
marrow
transplant
patient
recoveri
tand
blymphocyt
delay
neutrophil
recent
hematolog
transplant
patient
may
low
immunoglobulin
level
lung
transplant
patient
also
particularli
prone
seriou
viral
pneumonia
use
bcell
suppress
therapi
exampl
rituximab
may
also
predispos
progress
lrt
viral
infect
use
malign
immunoglobulinmedi
diseas
convers
acut
leukemia
chemotherapyinduc
neutropenia
may
import
role
sever
viral
infect
bacteri
fungal
infect
despit
increas
risk
hematolog
lung
transplant
recipi
patient
viral
pneumonia
viralinduc
ard
overtli
immunocompromis
given
frequenc
infect
common
respiratori
virus
adult
children
proport
develop
lrti
small
specif
genet
defect
normal
host
respons
viral
urt
infect
like
patient
extrem
manifest
four
gener
pattern
lrti
virus
commonli
seen
acut
bronchiti
bronchiol
adult
children
without
prior
lung
diseas
commun
respiratori
virus
acut
exacerb
obstruct
lung
diseas
asthma
chronic
obstruct
lung
diseas
copd
pneumonia
ard
potenti
benefit
nonspecif
therapi
increas
latter
wherea
support
therapi
alon
usual
adequ
airwayonli
involv
acut
bronchiol
children
exacerb
asthma
copd
far
common
reason
hospit
acut
viral
ill
whether
specif
antivir
therapi
improv
outcom
entiti
still
investig
data
influenza
antivir
exacerb
asthma
copd
mix
data
respons
variou
novel
agent
rsv
pend
howev
rsv
major
caus
pediatr
hospit
justif
treatment
airway
diseas
alon
avail
ongo
trial
involv
extrapulmonari
site
respiratori
viral
infect
clearli
increas
propens
treat
site
may
involv
respiratori
virus
list
tabl
viremia
occur
frequent
viral
lrti
although
report
other
howev
technolog
assess
viremia
past
poor
incomplet
studi
experi
human
immunodefici
viru
hiv
hepat
virus
assess
serum
viral
load
commonplac
may
lead
greater
use
whole
blood
viral
load
assess
indic
respons
therapi
respiratori
virus
serum
assay
adenoviru
commerci
avail
neurolog
complic
classic
ev
includ
prototyp
ev
strain
flaccid
paralysi
enceph
asept
mening
promin
featur
central
nervou
system
involv
influenza
includ
enceph
transvers
myeliti
asept
mening
rare
syndrom
case
viral
enceph
may
influenza
adult
children
enceph
associ
hmpv
case
report
pericard
myocard
classic
ev
strain
previous
call
coxsackieviru
coxsackieviru
routin
detect
current
commerci
avail
rvp
myocard
pericard
report
influenza
pandem
infrequ
report
sinc
howev
asian
epidem
sign
focal
diffus
myocard
found
third
autopsi
hepat
clearli
complic
sever
viral
respiratori
tract
infect
classic
adenoviru
ev
also
signific
risk
group
includ
hepat
ev
b
group
also
associ
hepat
rhabdomyolysi
report
viral
pneumonia
particularli
pandem
influenza
strain
multicent
report
patient
admit
intens
care
unit
found
creatinin
kinas
elev
greater
risk
renal
replac
therapi
prolong
ventil
vitro
studi
suggest
muscl
cell
also
express
sialic
acid
receptor
ident
receptor
influenza
use
bind
respiratori
epitheli
cell
rhabdomyolysi
therefor
seem
like
manifest
viremia
case
report
associ
rhabdomyolysi
respiratori
virus
well
clinic
respons
posit
rvp
take
varieti
form
mani
way
straightforward
respons
occur
specif
treatment
avail
influenza
potenti
rsv
manag
infect
virus
rvp
panel
requir
much
nuanc
approach
primari
clinic
question
provid
viral
diagnosi
lead
differenti
treatment
major
clinic
question
whether
posit
viral
diagnosi
patient
lrti
allow
safe
avoid
discontinu
antibiot
random
control
trial
specif
address
issu
pertin
public
beforeandaft
studi
introduct
multiplex
pcr
specif
institut
one
larg
studi
suggest
posit
rvp
decreas
antibiot
util
signific
impact
increas
antivir
use
pure
oseltamivir
decreas
chest
comput
tomographi
ct
scan
pertin
studi
pilot
random
control
trial
combin
serum
procalcitonin
multiplex
rvp
subject
nonpneumon
lrti
studi
subject
posit
rvp
significantli
less
discharg
antibiot
trend
toward
shorter
durat
antibiot
therapi
especi
high
protocol
adher
combin
low
procalcitonin
posit
rvp
also
demonstr
antibiot
observ
studi
pneumonia
true
random
control
trial
avail
current
data
suggest
posit
rvp
alon
insuffici
evid
discontinu
antibiot
howev
posit
rvp
seem
synergist
effect
procalcitonin
biomark
independ
associ
decreas
antibiot
therapi
decreas
durat
antibiot
therapi
avoid
antibiot
therapi
patient
pneumonia
seem
unlik
use
rvp
addit
posit
rvp
may
give
enough
clinic
assur
avoid
addit
diagnost
procedur
chest
ct
scan
bronchoscopi
patient
fail
empir
antibiot
therapi
contrast
avoid
antibiot
lrti
includ
acut
exacerb
copd
acut
simpl
bronchiti
base
posit
rvp
low
procalcitonin
may
clinic
safe
addit
decis
regard
antibiot
sever
clinic
relev
gener
treatment
may
affect
posit
rvp
initi
resurg
use
anticholinerg
bronchodil
recognit
postvir
cough
bronchospasm
seem
respond
better
anticholinerg
standard
bagonist
bronchodil
copd
exacerb
anticholinerg
standard
therapi
although
significantli
less
asthma
therefor
posit
rvp
may
suggest
need
add
anticholinerg
patient
previous
take
importantli
posit
rvp
may
gener
less
concern
prolong
exacerb
certain
virus
associ
prolong
bronchospasm
includ
rhinoviru
influenza
parainfluenza
rsv
situat
avoid
escal
corticosteroid
dose
durat
may
result
knowledg
viral
trigger
prospect
random
trial
address
issu
document
viral
pneumonia
caus
ard
increasingli
recogn
indic
venoven
vv
extracorpor
membran
oxygen
ecmo
improv
technic
aspect
ecmo
includ
simplif
membran
oxygen
vv
circuit
use
singl
cathet
taken
rare
intervent
becom
part
standard
armamentarium
tertiari
referr
center
recent
year
pneumonia
secondari
pandem
strain
becom
lead
nontranspl
indic
vvecmo
lrt
trophism
influenza
strain
predilect
previous
healthi
young
patient
may
main
reason
howev
respiratori
virus
associ
sever
ard
need
rescu
therapi
viralinduc
ard
less
like
respond
rescu
therapi
prone
posit
high
peep
addit
lack
reliabl
treatment
underli
diseas
seen
bacteri
pneumonia
may
push
clinic
care
toward
type
support
lack
specif
antivir
therapi
led
use
sever
gener
form
gener
reserv
patient
pneumonia
ard
patient
sever
immunocompromis
addit
often
use
combin
make
dissect
individu
benefit
difficult
posit
rvp
may
contraind
gener
antivir
therapi
patient
infect
sar
coronaviru
sever
pandem
viru
seem
worsen
use
system
corticosteroid
therefor
posit
rvp
may
indic
avoid
steroid
patient
ard
patient
organ
transplant
posit
rvp
may
consider
decreas
degre
immunosuppress
although
may
possibl
renal
transplant
solid
organ
transplant
combin
organ
reject
graft
versu
host
diseas
posit
rvp
often
lethal
combin
mainli
highdos
immunosuppress
decreas
rational
use
intraven
immunoglobulin
ivig
probabl
virusspecif
antibodi
present
pool
immunoglobulin
extract
multipl
peopl
pool
specimen
variabl
exposur
titer
virusspecif
antibodi
benefit
may
inconsist
plasma
patient
recent
recov
seriou
viral
infect
may
much
effect
limit
avail
data
rsv
antibodi
work
suggest
benefit
ivig
may
greatest
viremia
still
occur
may
stop
direct
celltoadjacentcel
spread
virus
ribavirin
guanosin
analog
seem
activ
broad
spectrum
rna
dna
virus
use
varieti
viral
respiratori
tract
infect
greatest
use
immunocompromis
popul
often
combin
ivig
ribavirin
treatment
attempt
sever
pneumonia
almost
virus
usual
rvp
unfortun
studi
uncontrol
nonblind
make
estim
true
benefit
ribavirin
difficult
determin
also
gave
immunomodul
includ
ivig
corticosteroid
obscur
potenti
benefit
aerosol
ribavirin
gener
fallen
disfavor
secondari
signific
teratogen
effect
difficulti
vent
drug
patient
room
without
potenti
affect
caregiv
visitor
oral
intraven
ribavirin
associ
hemolyt
anemia
sever
hypomagnesemia
requir
drug
discontinu
mani
case
recent
avail
differ
interferon
formul
explor
treatment
sever
viral
respiratori
infect
pharmaceut
interferon
medic
develop
princip
treatment
chronic
hepat
interferon
critic
part
normal
host
respons
respiratori
viral
infect
well
although
tempt
suspect
immunocompet
patient
develop
sever
viral
pneumonia
ard
may
alter
interferon
respons
limit
data
support
concept
greatest
support
interferon
combin
therapi
respiratori
viral
infect
come
historicalcontrol
cohort
seri
treatment
coronavirusinduc
mer
pegyl
interferon
weekli
week
daili
ribavirin
use
treat
subject
document
mer
earli
surviv
day
significantli
higher
histor
control
site
howev
sustain
surviv
demonstr
combin
interferon
ribavirin
also
seem
synergist
sar
coronaviru
use
treat
patient
ard
mani
pneumonia
although
frequenc
viral
pneumonia
unknown
small
pilot
studi
day
mortal
significantli
improv
compar
control
interferonb
also
use
aerosol
treat
viralinduc
exacerb
asthma
equivoc
result
combin
interferon
ribavirin
also
use
treat
refractori
seriou
rhinoviru
respiratori
tract
infect
patient
hypogammaglobulinemia
good
result
specif
antivir
treatment
pathogen
influenza
rsv
cidofovir
seriou
adenovir
pneumonia
releas
treatment
cytomegaloviru
retin
hiv
patient
intraven
cidofovir
use
immunocompromis
immunocompet
patient
treatment
clearli
effect
immunocompet
immunocompromis
patient
cidofovir
signific
nephrotox
adenovir
serum
titer
measur
commerci
avail
assist
determin
durat
therapi
although
dose
weekli
usual
suffici
patient
like
respond
pleconaril
studi
neonat
ev
sepsi
success
result
possibl
use
seriou
enterovir
rhinovir
respiratori
tract
infect
studi
drug
clinic
avail
yet
side
effect
seem
toler
pcrbase
diagnosi
becom
standard
viral
pneumonia
respiratori
tract
infect
expans
rvp
outsid
influenza
possibl
rsv
led
abil
diagnos
viral
infect
approv
specif
antivir
treatment
exist
care
clinic
evalu
patient
posit
rvp
therefor
critic
given
limit
repertoir
treatment
gener
treatment
ivig
ribavirin
interferon
may
benefit
select
sever
viral
pneumonia
patient
wherea
cidofovir
activ
sever
adenovir
pneumonia
develop
new
treatment
add
signific
valu
abil
detect
viral
respiratori
pathogen
